| Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More | Sarah de Crescenzo | 08/21/20 | National |
| J&J Boosts Autoimmune Disease Drug Pipeline With $6.5B Momenta Buyout | Frank Vinluan | 08/19/20 | New York |
| Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy | Sarah de Crescenzo | 08/17/20 | New York |
| Advisory Body Backs MesoBlast Therapy for Transplant Complication | Sarah de Crescenzo | 08/14/20 | New York |
| CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears | Frank Vinluan | 08/14/20 | Europe |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor | Frank Vinluan | 08/12/20 | New York |
| Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia | Sarah de Crescenzo | 08/12/20 | San Francisco |
| F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections | Frank Vinluan | 08/12/20 | Europe |
| Pfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political | Derrick Gingery | 08/12/20 | National |
| Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy | Frank Vinluan | 08/11/20 | Europe |
| Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More | Sarah de Crescenzo | 08/07/20 | National |
| As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up | Frank Vinluan | 08/05/20 | New York |
| Still Stuck on Adhesion Issues, FDA Rejects DBV’s Peanut Allergy Patch | Sarah de Crescenzo | 08/04/20 | National |
| Kymera Therapeutics Unveils IPO Pitch for Protein Degradation | Frank Vinluan | 07/31/20 | Boston |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Pfizer, BioNTech Choose Full Spike Protein for Pivotal Vaccine Test | Frank Vinluan | 07/28/20 | New York |
| Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More | Sarah de Crescenzo | 07/24/20 | National |
| FDA Lifts CymaBay Drug Hold, Tests to Resume in Rare Liver Disease PBC | Frank Vinluan | 07/23/20 | San Francisco |
| Elevation Oncology Debuts With $32.5M to Develop Targeted Cancer Drugs | Sarah de Crescenzo | 07/21/20 | New York |
| Forge Bio’s Combo Model for Gene Therapies Attracts $40M in Funding | Frank Vinluan | 07/21/20 | National |
| MeiraGTx, J&J See Phase 3 Test Ahead for Vision Loss Gene Therapy | Sarah de Crescenzo | 07/17/20 | New York |
| Two Days, Six IPOs, and $1B Raised for Biotech Research & More | Frank Vinluan | 07/17/20 | National |
| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Mallinckrodt’s Kidney Failure Drug Narrowly Wins Backing of FDA Panel | Frank Vinluan | 07/16/20 | Europe |
| Moderna Publishes Early COVID-19 Vaccine Data, Preps for Phase 3 Test | Frank Vinluan | 07/15/20 | Boston |
| Last Chance for Xconomy Awards Nominations – Deadline is Friday, July 17 | Editors | 07/15/20 | Boston |
| 3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments | Sarah de Crescenzo | 07/13/20 | National |
| Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More | Sarah de Crescenzo | 07/10/20 | National |
| Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership | Sarah de Crescenzo | 07/09/20 | Boston |
